Pancreatic cancer has long ranked among the most unforgiving diagnoses in oncology. Patients often learn of their disease only after it has spread. Median survival in the metastatic setting hovers below a year. Standard chemotherapy brings modest extensions of life at the cost of significant toxicity. Against that backdrop, results from a 500-patient phase 3 trial landed with force at the American Society of Clinical Oncology meeting in Chicago on May 31. The oral drug daraxonrasib, developed by Revolution Medicines, produced a median overall survival of 13.2 months. Patients assigned to investigator’s choice of second-line chemotherapy lived a median of 6.7 months. The hazard ratio for death stood at 0.40. Statistical significance crossed well beyond the conventional threshold. Progression-free survival showed a similar pattern. Tumors stayed under control for 7.2 months on the pill versus 3.6 months on chemotherapy.…